Accessibility Menu
Agenus logo

Agenus(NASDAQ) AGEN

Market Cap$364.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-93%
1 Year+77%
1 Month+46%
$8.14
+8.68%
+0.65Today
After hours$8.08-$0.06 (-0.74%)
Agenus last closing stock price
MetricPriceDate
Last closeUSD 8.092026-08-21
Agenus stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.52%USD 7.322026-08-14
1 month+46.29%USD 5.532026-07-22
3 month+160.13%USD 3.112026-05-22
Year to date+157.64%USD 3.142025-12-31
1 year+77.02%USD 4.572025-08-21
3 year-73.21%USD 30.202023-08-22
5 year-93.19%USD 118.742021-08-20
Since inception-99.89%USD 7,227.312000-02-04

Agenus Financials at a Glance

Market Cap

$364.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$132.69M

Net Income (TTM)

$92.01M

EPS (TTM)

$2.65

P/E Ratio

3.05

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Price

$8.14

Volume

1,517,511.822

Open

$7.58

Previous Close

$8.09

Daily Range

$7.58 - $8.35

52-Week Range

$2.71 - $8.85

Estimated Earnings Date

Nov 9, 2026

AGEN News

Foolcom-Featured.png

Agenus Posts 48% Q2 Revenue Miss

Motley Fool Markets TeamAug 11, 2025
young-woman-holding-thumbs-up

3 Magnificent Growth Stocks to Buy Hand Over Fist

George Budwell, PhDMay 22, 2024
time to buy

Up 40%: Is This Red-Hot Growth Stock Still a Buy?

George Budwell, PhDApr 28, 2024
angry-investor-2-getty

Down 75%. Is Agenus Stock a Buy on the Dip?

Cory RenauerApr 8, 2024
Medical professional with hand on head

Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

Eric VolkmanFeb 15, 2024
growth curve

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

George Budwell, PhDDec 24, 2023
time to buy

3 Magnificent Growth Stocks to Buy on the Dip

George Budwell, PhDAug 28, 2023
thumbnail_oral medications

2 Low-Priced Stocks That Could Make You Richer

George Budwell, PhDJun 26, 2023
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Agenus

Agenus Inc. makes medicines that help the body fight cancer. These treatments teach the immune system to find tumors. The company also makes ingredients that improve how vaccines work.

Medicines and Methods

  • BOT and BAL: Experimental antibodies that work together to help immune cells find and kill cancer cells.
  • QS-21 Stimulon: Adjuvant used in vaccines to help the body create a stronger immune defense.
  • Antibody Platforms: Technology used to discover and build new monoclonal antibody treatments for various diseases.
  • Cell Therapies: Early-stage treatments using specific immune cells to target and kill cancer cells.

Growing the Business

  • Sold manufacturing facilities in California to Zydus Lifesciences in January 2026 for $91 million.
  • Prioritized the development of its lead therapy combination for colon cancer in July 2026.
  • Partnered with BAP Pharma in April 2026 for global drug distribution services.
  • Secured $85 million in upfront proceeds through a private placement of stock in July 2026.

Why This Approach Matters

Agenus maintains a deep library of proprietary assets targeting immune checkpoints, which are proteins that act as brakes on the immune system. Its Zydus collaboration provides long-term manufacturing capacity while reducing internal headcount and fixed operating costs.

The Financial Scorecard

  • Non-cash royalty revenue reached $28.1 million for the three months ended June 30, 2026, up $3.3 million year over year.
  • Research and development expense decreased 45% to $14.8 million for the three months ended June 30, 2026.
  • The company reported a $40.4 million gain from selling manufacturing assets in the six months ended June 30, 2026.
  • Cash and cash equivalents totaled $18.7 million as of June 30, 2026.

Bottom Line

Agenus has transitioned from a manufacturing-heavy operation to a leaner, clinical-stage developer focused on high-value oncology programs. This shift helps the company concentrate resources on lead therapy candidates while managing a significant accumulated deficit.

AI Generated • Aug 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

81

CEO

Garo H. Armen, PhD

Website

www.agenusbio.com

Headquarters

Lexington, MA 02421-7305, US

AGEN Financials

Key Financial Metrics (TTM)

Gross Margin

75.63%

Operating Margin

27.28%

Net Income Margin

69.34%

Return on Equity

-38.12%

Return on Capital

-32.23%

Return on Assets

53.28%

Earnings Yield

32.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$364.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.02M

Volume

1.52M

Avg. Volume

4.18M

Financials (TTM)

Gross Profit

$100.36M

Operating Income

$36.20M

EBITDA

$155.79M

Operating Cash Flow

-$98.50M

Capital Expenditure

$0.00

Free Cash Flow

-$98.50M

Cash & ST Invst.

$18.74M

Total Debt

$40.71M

Agenus Performance Analysis

Agenus annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 98,024,000-66.8%
20232023-12-31USD 156,314,00059.5%
20242024-12-31USD 103,463,000-33.8%
20252025-12-31USD 114,196,00010.4%
Agenus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3017.7%
Q42025-12-3113.1%
Q12026-03-31-1.4%
Q22026-06-302.3%
Agenus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -15.64641.5%
20232023-12-31USD -13.75-12.1%
20242024-12-31USD -10.59-22.9%
20252025-12-31USD -0.00-100.0%
Agenus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30294.0%
Q42025-12-31-115.5%
Q12026-03-31440.0%
Q22026-06-30-101.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$34.52M

+34.4%

Gross Profit

$34.52M

+2835.2%

Gross Margin

100.00%

N/A

Market Cap

$364.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.50M

N/A

Employees

81

N/A

Net Income

-$550.00K

+98.0%

EBITDA

$15.19M

+212.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$18.74M

+96.5%

Total Debt

$40.71M

-55.0%

Accounts Receivable

$14.73M

+1976.9%

Inventory

$0.00

N/A

Long Term Debt

$9.54M

-87.5%

Short Term Debt

$31.17M

+122.9%

Return on Assets

53.28%

N/A

Return on Invested Capital

-61.22%

N/A

Free Cash Flow

-$31.20M

-54.3%

Operating Cash Flow

-$31.20M

-54.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IRDOpus Genetics, Inc.
$4.05-1.70%
TTRXTurn Therapeutics Inc.
$9.46-0.84%
ZNTLZentalis Pharmaceuticals, Inc.
$3.83-0.39%
FATEFate Therapeutics, Inc.
$2.33-4.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About AGEN

What is the current price of Agenus?

Agenus is trading at $8.09 per share.

What is the 52-week range for Agenus?

Over the past 52 weeks, Agenus has traded between $2.71 and $8.85.

How much debt does Agenus have?

As of the most recent reporting period, Agenus reported total debt of $290.17M.

How much cash does Agenus have on hand?

Agenus reported $18.74M in cash and cash equivalents in its most recent financial results.

What is Agenus’s dividend yield?

Agenus does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services